TMA-2

2,4,5-Trimethoxyamphetamine

DOMeO, 2,5-Dimethoxy-4-methoxyamphetamine

Psychoactive Class

Chemical Class

Amphetamine (psychedelic)Phenethylamine (substituted)

TMA-2 is a synthetic psychedelic of the substituted amphetamine class and a member of the trimethoxyamphetamine family. First synthesized by Viktor Bruckner in 1933, its psychoactive properties were identified by Alexander Shulgin in 1962.¹ Structurally related to mescaline but considerably more potent,¹ it produces a distinctive combination of hallucinogenic, stimulant, and entactogenic effects. TMA-2 remains an obscure research chemical that is rarely encountered outside of online vendor markets.

Dosage & Duration

Dosage

Threshold~5 mg

Light5-20 mg

Moderate20-40 mg

Strong40-60 mg

Heavy60+ mg

TMA-2 is reported to be highly unpredictable and dose-sensitive, with a narrow margin between psychoactive and toxic doses. Anecdotal reports indicate variable effects including body load, nausea, and overstimulation.

Duration

Onset20-120 minutes

Peak4-6 hours

Offset2-4 hours

After Effects4-24 hours

Total8-12 hours

Subjective Effects

TMA-2 produces a mescaline-like psychedelic state layered over mild stimulation, with a notably slow onset — effects may take an hour or more to appear before building to full intensity over the following hour. The character of the experience is frequently described as calm, benign, and peaceful, with an absence of dark or threatening undercurrents, and a somewhat hypnotic quality that can leave users unusually receptive to suggestion. The total duration runs roughly ten to twelve hours, with a fairly rapid drop-off in the later hours at some doses.

Physical

Mental and physical stimulation accompany the experience, alongside come-up discomforts such as nausea, light tremors, and brief intestinal cramping. Pupil dilation, appetite suppression, muscle tension, sweating and chills, and difficulty sleeping toward the end of the experience are also reported.

Autonomic

Appetite suppression

Uncomfortable

Muscle tension

Cognitive

The headspace is calm and lucid, with clear thinking, euphoria, enhanced empathy, insight, and a gently cosmic or ego-softening quality. Time can seem to pass very slowly in the first hours, and mild, non-troublesome confusion is sometimes reported.

Emotional

Empathy enhancement

Enhancements

Visual

Visuals are moderate and well-mannered rather than overwhelming, closely resembling mescaline apart from less intense color enhancement.

Auditory

Tactile

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

TMA-2 acts as a partial agonist at serotonin 5-HT2A receptors, which is believed to be the primary mechanism underlying its psychedelic effects.² It also shows broader activity at the 5-HT2 receptor family.²

Pharmacokinetics

In rat studies, the 4-methoxyl group undergoes preferential O-demethylation, with approximately 20% of that methoxyl carbon appearing as expired carbon dioxide. This rate is roughly four times that observed for either of the other two methoxyl groups, indicating the 4-position is the primary site of oxidative demethylation.³

Metabolitesnone documented yet

Tolerance

Full Tolerance

Tolerance to the effects of TMA-2 develops almost immediately after ingestion.

Baseline Reset

Approximately 7 days in the absence of further consumption

Half Tolerance

Approximately 3 days

Cross Tolerance

Psychedelics

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

TMA-2 is considered to have extremely low addiction potential due to its psychedelic nature. It is not habit-forming and the desire to use it can actually decrease with repeated use, making it largely self-regulating.

Toxicity

Cardiovascular

High doses in rats caused bradycardia and hypothermia;¹ in humans, vasoconstriction and increased blood pressure have been reported at higher doses, though human data remains extremely limited.

Psychosis Risk

Mental health risks are assumed to be similar to those associated with other hallucinogens. Psychedelic-crisis management is appropriate for acute anxiety and panic reactions. More severe psychotic reactions may occur, especially when someone's family history includes schizophrenia or early-onset mental illness, since psychedelics have been known to trigger latent psychological conditions.

Seizure Risk

Toxicity studies in rats showed that doses of 80 mg/kg induced frequent clonic convulsions.¹ Given the reported narrow margin between active and toxic doses,¹ seizure risk may be elevated at higher dosages. Individuals with seizure or convulsive disorders are advised to exercise particular caution.

History & Culture

TMA-2 was first synthesized by Hungarian chemist Viktor Bruckner in 1933⁴, but its psychoactive properties remained unrecognized for nearly three decades. Alexander Shulgin independently synthesized the compound in…

Legality

International

UN Convention on Psychotropic Substances 1971 (Schedule I)

EU Council Decision (December 2003) - requiring member states to implement control measures within 90 days⁷

By Country

United StatesSchedule I

Controlled as a positional isomer of TMA, which is explicitly listed as a Schedule I hallucinogen under the Controlled Substances Act.¹² Manufacturing, possession, and distribution are prohibited.

BelgiumIllegal

Added to the list of illegal psychotropic substances on November 8, 2004.¹

FinlandControlled

Classified as a controlled substance under Finnish drug legislation.¹

GreeceControlled

Became a controlled substance on February 18, 2003.¹

ItalyTabella I

Added to Tabella I (list of prohibited plants and substances) by Ministry of Health decree on January 11, 2005.¹

SlovakiaGrade 2

Added to Grade 2 (corresponding to Schedule II of the 1971 UN Convention on Psychotropic Substances) in October 2009.

SwitzerlandControlled (Verzeichnis D)

Specifically named as a controlled substance under Verzeichnis D of Swiss controlled substances legislation.⁹

United KingdomClass A

Controlled as a Class A drug under the Misuse of Drugs Act 1971.¹¹ Covered by the generic phenethylamine definition as a positional isomer of the UN-controlled drug TMA. Class A classification carries the most severe penalties.

AustriaIllegal (SMG)

Prohibited under the Suchtmittelgesetz (Narcotics Act). Possession, production, and sale are illegal.¹

CanadaSchedule III (CDSA)

Listed as 2,4,5-trimethoxyamphetamine in Schedule III of the Controlled Drugs and Substances Act. Possession and sale are prohibited.

GermanyAnlage I BtMG

Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since October 10, 1999.⁸ Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are illegal.

IrelandSchedule 1

Ireland applies Misuse of Drugs Act controls to TMA-2 through its status as a positional isomer of UN-listed TMA, comparable to UK scheduling.¹

PortugalControlled

Control measures enacted in January 2005 alongside 2C-I, 2C-T-2, and 2C-T-7.¹

SwedenClass I

Placed into Class I (most restrictive category) as of March 16, 2004.¹

TurkeyIllegal

Classified as a controlled drug under Turkish law. Possession, production, supply, and import are prohibited.¹⁰

References

Source Pages

Citations

Suggest an edit